Abstract
Protein kinases are important enzymes in solid tumour and leukaemia pathologies. Their structures are well understood at the atomic level and their key role in the progression of certain cancers makes them valuable targets for anti-cancer therapy. Through medicinal chemical approaches, we developed an efficient preparative stereospecific synthesis of N12, N13 pyran-bridged indolocarbazoles that opens access to functional diversity within this previously challenging series. We focused upon the indolocarbazole class of chemical inhibitors, which includes S27888, an inhibitor we previously identified. We used biochemical and cell-based assays to identify small molecule inhibitors of Checkpoint kinase 1 (Chk1), a serine/threonine protein kinase that is activated when cancer cells are treated with genotoxic agents. These compounds show a promising inhibitory profile on Chk1. Furthermore, these compounds are active against FLT3, which is a tyrosine kinase that is frequently activated in human leukaemias. These data suggest that this chemical class may provide a source of therapeutic compounds for a broad range of human cancers.
Keywords: Checkpoint kinase 1, Chk1, FLT3, Checkpoint adaptation, Genotoxic agents, HT29 cells, Indolocarbazoles, Protein kinases, Stereospecific synthesis, antiproliferative properties
Anti-Cancer Agents in Medicinal Chemistry
Title: Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Volume: 12 Issue: 3
Author(s): Francoise M. Perron-Sierra, Nathalie Kucharkzyk, Celine Boucley, Christel Guyard-Daumas, Sophie Sciberras, Christine Fouache, Sabine Plantier, Aurelie Studeny, Celine Bossard, Patrick J. Casara and Roy M. Golsteyn
Affiliation:
Keywords: Checkpoint kinase 1, Chk1, FLT3, Checkpoint adaptation, Genotoxic agents, HT29 cells, Indolocarbazoles, Protein kinases, Stereospecific synthesis, antiproliferative properties
Abstract: Protein kinases are important enzymes in solid tumour and leukaemia pathologies. Their structures are well understood at the atomic level and their key role in the progression of certain cancers makes them valuable targets for anti-cancer therapy. Through medicinal chemical approaches, we developed an efficient preparative stereospecific synthesis of N12, N13 pyran-bridged indolocarbazoles that opens access to functional diversity within this previously challenging series. We focused upon the indolocarbazole class of chemical inhibitors, which includes S27888, an inhibitor we previously identified. We used biochemical and cell-based assays to identify small molecule inhibitors of Checkpoint kinase 1 (Chk1), a serine/threonine protein kinase that is activated when cancer cells are treated with genotoxic agents. These compounds show a promising inhibitory profile on Chk1. Furthermore, these compounds are active against FLT3, which is a tyrosine kinase that is frequently activated in human leukaemias. These data suggest that this chemical class may provide a source of therapeutic compounds for a broad range of human cancers.
Export Options
About this article
Cite this article as:
M. Perron-Sierra Francoise, Kucharkzyk Nathalie, Boucley Celine, Guyard-Daumas Christel, Sciberras Sophie, Fouache Christine, Plantier Sabine, Studeny Aurelie, Bossard Celine, J. Casara Patrick and M. Golsteyn Roy, Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228823
DOI https://dx.doi.org/10.2174/187152012800228823 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals Quassinoids from Brucea Javanica Seeds Inhibiting the Replication of Tobacco Mosaic Virus
Current Bioactive Compounds MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Current Pharmaceutical Design Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design The Expanding Role of Tumor Necrosis Factor-α Inhibitors in the Management of Rheumatic Diseases
Medicinal Chemistry Reviews - Online (Discontinued) Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets